Shingles Vaccine Market Growth, Size, Trends Analysis - By Product, By Vaccine Type - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,520	244 Pages	SPER Market Research Pvt. Ltd.	April, 2025	SPER20068078

Best Price Guarantee
Price	from $4,520
Length	244 Pages
Publisher	SPER Market Research Pvt. Ltd.
Published Date	April, 2025
SKU	SPER20068078

Table of Contents
Description

Shingles Vaccine Market Introduction and Overview

According to SPER market research, ‘Global Shingles Vaccine Market Size- By Product, By Vaccine Type – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Shingles Vaccine Market is predicted to reach 20.9 billion by 2034 with a CAGR of 15.58%.

The shingles vaccine is a prophylactic vaccination intended to guard against shingles, a painful rash brought on by the varicella-zoster virus (VZV), which is also the virus that triggers chickenpox. Postherpetic neuralgia (PHN) and other shingles consequences are less likely to occur when it strengthens the immune system’s reaction. Due to an increased risk of shingles with age, the vaccine is mostly advised for older persons. The more modern recombinant vaccination (Shingrix), which is very effective, and the older live attenuated vaccine (Zostavax), which is less widely used, are the two primary varieties.

Restraints:

The high cost of the shingles vaccine restricts accessibility, particularly in low-income areas, and is one of the market’s many obstacles. Adoption is further hampered by misunderstandings and a lack of knowledge on shingles and vaccination. Issues with the supply chain, such as complicated distribution and storage, impact availability. There is still worry about vaccination reluctance brought on by mistrust of immunization programs and fear of adverse consequences. The launch of novel vaccines is delayed by regulatory obstacles and drawn-out approval procedures.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered

By Product, By Vaccine Type

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

GlaxoSmithKline plc., Pfizer Inc., Merck & Co., Inc., CanSinoBIO, Vaccitech, Green Cross Corp, Geneone Life Science, SK Bioscience.

Global Shingles Vaccine Market Segmentation:

By Product:

Based on the Product, Global Shingles Vaccine Market issegmented as; Shingrix, Zostavax, SKYZoster.

By Vaccine Type:

Based on the Vaccine Type, GlobalShingles Vaccine Market is segmented as; Recombinant Vaccine, Live AttenuatedVaccine.

By Region:

This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East& Africa.

1. Introduction: 1.1. Scope of the report; 1.2. Market segment analysis
2. Research Methodology: 2.1. Research data source; 2.1.1. Secondary Data; 2.1.2. Primary Data; 2.1.3. SPERâ€™s internal database; 2.1.4. Premium insight from KOLâ€™s; 2.2. Market size estimation; 2.2.1. Top-down and Bottom-up approach; 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics: 4.1. Driver, Restraint, Opportunity and Challenges analysis; 4.1.1. Drivers; 4.1.2. Restraints; 4.1.3. Opportunities; 4.1.4. Challenges
5. Market variable and outlook: 5.1. SWOT Analysis; 5.1.1. Strengths; 5.1.2. Weaknesses; 5.1.3. Opportunities; 5.1.4. Threats; 5.2. PESTEL Analysis; 5.2.1. Political Landscape; 5.2.2. Economic Landscape; 5.2.3. Social Landscape; 5.2.4. Technological Landscape; 5.2.5. Environmental Landscape; 5.2.6. Legal Landscape; 5.3. PORTERâ€™s Five Forces; 5.3.1. Bargaining power of suppliers; 5.3.2. Bargaining power of buyers; 5.3.3. Threat of Substitute; 5.3.4. Threat of new entrant; 5.3.5. Competitive rivalry; 5.4. Heat Map Analysis
6. Competitive Landscape: 6.1. Global Shingles Vaccine Market Manufacturing Base Distribution, Sales Area, Product Type; 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Shingles Vaccine Market
7. Global Shingles Vaccine Market, By Product 2021-2034 (USD Million): 7.1. Shingrix; 7.2. Zostavax; 7.3. SKYZoster
8. Global Shingles Vaccine Market, By Vaccine Type 2021-2034 (USD Million): 8.1. Recombinant Vaccine; 8.2. Live Attenuated Vaccine
9. Global Shingles Vaccine Market, 2021-2034 (USD Million): 9.1. Global Shingles Vaccine Market Size and Market Share
10. Global Shingles Vaccine Market, By Region, 2021-2034 (USD Million): .1. Asia-Pacific; 10.1.1. Australia; 10.1.2. China; 10.1.3. India; 10.1.4. Japan; 10.1.5. South Korea; 10.1.6. Rest of Asia-Pacific; 10.2. Europe; 10.2.1. France; 10.2.2. Germany; 10.2.3. Italy; 10.2.4. Spain; 10.2.5. United Kingdom; 10.2.6. Rest of Europe; 10.3. Middle East and Africa; 10.3.1. Kingdom of Saudi Arabia; 10.3.2. United Arab Emirates; 10.3.3. Qatar; 10.3.4. South Africa; 10.3.5. Egypt; 10.3.6. Morocco; 10.3.7. Nigeria; 10.3.8. Rest of Middle-East and Africa; 10.4. North America; 10.4.1. Canada; 10.4.2. Mexico; 10.4.3. United States; 1.5. Latin America; 10.5.1. Argentina; 10.5.2. Brazil; 10.5.3. Rest of Latin America
11. Company Profile: 11.1. BioNTech SE; 11.1.1. Company details; 11.1.2. Financial outlook; 11.1.3. Product summary; 11.1.4. Recent developments; 11.2. CanSinoBIO; 11.2.1. Company details; 11.2.2. Financial outlook; 11.2.3. Product summary; 11.2.4. Recent developments; 1.3. CanSinoBIO; 11.3.1. Company details; 11.3.2. Financial outlook; 11.3.3. Product summary; 11.3.4. Recent developments; 11.4. Geneone Life Science; 11.4.1. Company details; 11.4.2. Financial outlook; 11.4.3. Product summary; 11.4.4. Recent developments; 11.5. GlaxoSmithKline plc.; 11.5.1. Company details; 11.5.2. Financial outlook; 11.5.3. Product summary; 11.5.4. Recent developments; 11.6. Green Cross Corp; 11.6.1. Company details; 11.6.2. Financial outlook; 11.6.3. Product summary; 11.6.4. Recent developments; .7. Merck & Co., Inc.; 11.7.1. Company details; 11.7.2. Financial outlook; 11.7.3. Product summary; 11.7.4. Recent developments; 11.8. Pfizer Inc.; 11.8.1. Company details; 11.8.2. Financial outlook; 11.8.3. Product summary; 11.8.4. Recent developments; 11.9. SK Bioscience; 11.9.1. Company details; 11.9.2. Financial outlook; 11.9.3. Product summary; 11.9.4. Recent developments; 11.10. Vaccitech; 11.10.1. Company details; 11.10.2. Financial outlook; 11.10.3. Product summary; 11.10.4. Recent developments; 11.11. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links